Examining the link between venetoclax levels and remission in adults with acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between venetoclax plasma concentrations and remission outcomes in adults with acute myeloid leukemia (AML) who are ineligible for standard chemotherapy. It aims to compare the mean residual venetoclax levels in patients who achieve complete remission versus those who do not after the first cycle of treatment with venetoclax and azacitidine. The study will involve blood sampling for drug dosage and will include adult patients aged 60 and older with a confirmed diagnosis of AML. The study is conducted in compliance with French law and is designed to have minimal risks for participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subject must have a confirmed diagnosis of previously untreated AML (ELN 2022 criteria) within 28 days of the onset of symptoms. Only previous cytoreductive treatments (e.g. hydroxyurea) are authorized.
2. Subject must be ineligible for standard cytarabine and anthracycline induction therapy according to the following criteria:

   * Subject aged ≥ 75 years.
   * OR subject aged between 60 and 74 with at least one of the following comorbidities:

     * ECOG performance status: of 2 or 3.
     * cardiac history: heart failure requiring treatment, left ventricular ejection fraction ≤ 50%, chronic stable angina.
     * carbon monoxide diffusion capacity ≤ 65% or forced expiratory volume in one second ≤ 65%.
     * creatinine clearance between 30 and 45 mL/min/m².
     * liver damage (not related to AML) with total bilirubin between 1.5 and 3 × upper normal limit.
     * any other comorbidity deemed by the physician to be incompatible with standard induction chemotherapy.
3. Patients are eligible for the recommended standard treatment, i.e. a combination of venetoclax and a hypomethylating agent.
4. Subjects must voluntarily sign and date an informed consent form authorized by the relevant authorities.
5. The participation of the subject in another interventional study not interfering with the pathophysiological, pharmacological and clinical rationale of this protocol is possible.

Exclusion Criteria:

1. blood leukocytes \>25 G/L.
2. Subject has already received anticancer treatment (drugs, surgery, radiotherapy) for AML, hematological malignancy or malignant cancer (within the last 2 years).
3. Subjects with AML with central nervous system involvement or promyelocytic type (AML-M3).
4. Subject to an uncontrolled intercurrent disease such as:

   * infection (viral, bacterial or fungal) requiring treatment;
   * symptomatic congestive heart failure;
   * unstable angina pectoris
   * cardiac arrhythmia
   * psychiatric illness or drug addiction that would limit compliance with study requirements (risk of treatment non-adherence or low venous capital).
5. Documented hypersensitivity to the drugs used to treat the subject.
6. Subject has been exposed to potent CYP450 inducers or inhibitors (including grapefruit, Seville oranges) within 7 days prior to treatment initiation.

Where it's running

• CHU de Caen
  Caen, France Recruiting

Study contacts

• Principal investigator: Pierre-Marie Morice, PharmD, PhD — University Teaching Hospital of Caen
• Study coordinator: Sylvain Chantepie, MD
• Email: chantepie-s@chu-caen.fr
• Phone: +33231272107

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• WBC100 capsules for adults with relapsed or refractory acute myeloid leukemia

  This trial will test whether taking WBC100 capsules once daily is safe and can help induce remission in adults with relapsed or refractory acute myeloid leukemia.

  Recruiting Phase 1 Hangzhou Weben Pharma Co., Ltd · Hangzhou, Zhejiang · NCT07014449

• Evaluating a new treatment for recurrent adult acute myeloid leukemia and myelodysplastic syndrome

  This study is testing a new combination treatment for adults with recurrent acute myeloid leukemia and myelodysplastic syndrome to see if it works better than current options.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06329999

• Mocravimod treatment for AML patients undergoing transplant

  This study is testing if a new treatment called mocravimod can help adults with acute myeloid leukemia who are getting a stem cell transplant feel better and have better outcomes compared to a placebo.

  Recruiting at 64 sites Phase 3 Priothera SAS · Birmingham, Alabama and 110 other locations · NCT05429632

• Venetoclax and Azacitidine with or without Quizartinib in older/unfit adults with AML

  This trial tests whether adding Quizartinib to Venetoclax and Azacitidine helps older or unfit adults with AML live longer compared with the standard Venetoclax and Azacitidine therapy.

  Recruiting at 24 sites Phase 3 PETHEMA Foundation · Santiago de Compostela, A Coruña and 51 other locations · NCT07478991

• Combining revumenib with azacitidine and venetoclax for treating specific types of acute myeloid leukemia

  This study is testing a new combination of medications to see if it can help people with specific types of acute myeloid leukemia who can't have intensive chemotherapy.

  Recruiting at 128 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · Los Angeles, California and 200 other locations · NCT06652438

• Comparing different drug combinations for newly diagnosed acute myeloid leukemia

  This study is testing different combinations of drugs to see which one works best for people with newly diagnosed acute myeloid leukemia who can't handle strong chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06532552

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.